Jian Campian

Associate Professor of Medicine, Associate Professor of Neurological Surgery

    • Source: Scopus
    20042020

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    My prior graduate research training, internal medicine residency as well as my medical oncology and neuro-oncology fellowship training will allow me to be well suited for translational research that bridges basic science and clinical medicine in neurological cancers. This prior experience prepared me well for a career path as an early-phase clinical trial investigator, with an emphasis on improving care for brain tumor patients. My interest on lymphopenia was sparked after an observation of increased PCP infection in brain tumor patients who were treated with radiation and steroid. I have found that 40-50% cancer patients developed severe lymphopenia after concurrent chemoradiation. Our studies have demonstrated that treatment-related lymphopenia is common, severe and long lasting in various solid tumors including glioblastoma, pancreatic cancer, non-small cell lung cancer, head and neck squamous carcinoma, rectal cancer etc. More importantly, this treatment-related lymphopenia is associated with inferior survival and patients died from tumor progression not opportunistic infections. Thus, my research has been focused on how to correct treatment-related lymphopenia in patients with malignant brain tumors, with an ultimate goal to improve overall survival in this deadly disease.

    Areas of Clinical Interest

    Neuro-oncology, immunotherapy, brain tumors, medical oncology

    Fingerprint

    Dive into the research topics where Jian Campian is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
    • 14 Similar Profiles

    Network

    Recent external collaboration on country level. Dive into details by clicking on the dots.
    If you made any changes in Pure these will be visible here soon.